| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b5f41889212134f724ee94357d02f4b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 |
| filingDate |
2021-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_206649450d52ba44c2e3f1e7878066e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ea8e24a2015133f9668fd9577bc7223
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb6a0a9ccd6e755f9ef3b4d92867dcbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d58cdf7ec45a167f78b82c42e20c22d |
| publicationDate |
2022-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20220154344-A |
| titleOfInvention |
Cancer immunotherapy composition comprising a statin as an active ingredient |
| abstract |
The present invention relates to an immuno-anticancer agent composition comprising a statin as an active ingredient, and the immuno-anticancer agent comprising the statin or a pharmaceutically acceptable salt thereof as an active ingredient expresses PD-L1 (Programmed death-ligand 1) By inhibiting PD-L1 and PD-1 from binding, the immune function of T cells is maintained and cancer cells are killed. |
| priorityDate |
2021-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |